Who are BCX4161's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): recombinant human C1 inhibitor, AVACINCAPTAD PEGOL SODIUM, Veopoz, Ultomiris, H5G1.1, C1 inhibitor (human) [C1 INH].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bcx4161.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

BCX4161 — Competitive Intelligence Brief

BCX4161 (BCX4161) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement inhibitor. Area: Immunology.

phase 2 Complement inhibitor C1 inhibitor Immunology Small molecule Live · refreshed every 30 min

Target snapshot

BCX4161 (BCX4161) — BioCryst Pharmaceuticals. BCX4161 is a small molecule inhibitor of the C1 inhibitor of the complement system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BCX4161 TARGET	BCX4161	BioCryst Pharmaceuticals	phase 2	Complement inhibitor	C1 inhibitor
recombinant human C1 inhibitor	recombinant human C1 inhibitor	Pharming Technologies B.V.	phase 3	Complement system regulator	C1 inhibitor
AVACINCAPTAD PEGOL SODIUM	AVACINCAPTAD PEGOL SODIUM		marketed	Complement Inhibitors	Complement C5	2023-01-01
Veopoz	POZELIMAB	Regeneron	marketed	Complement Inhibitor [EPC]	Complement C5	2023-01-01
Ultomiris	RAVULIZUMAB	AstraZeneca	marketed	Complement Inhibitor [EPC]	Complement C5	2018-01-01
H5G1.1	ECULIZUMAB	AstraZeneca	marketed	Complement Inhibitor [EPC]	C5	2007-01-01
C1 inhibitor (human) [C1 INH]	C1 inhibitor (human) [C1 INH]	Shire	marketed	Complement inhibitor / Serine protease inhibitor	C1s protease / Classical complement pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-11 — AVACINCAPTAD PEGOL SODIUM · 8236773 · Method of Use · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 9617546 · Compound · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 7579456 · Compound · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11491176 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11273171 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 12016875 · Method of Use · US

Sponsor landscape (Complement inhibitor class)

CSL Behring · 3 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Aldeyra Therapeutics, Inc. · 1 drug in this class
BioCryst Pharmaceuticals · 1 drug in this class
Haaglanden Medical Centre · 1 drug in this class
InflaRx GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BCX4161 — Competitive Intelligence Brief. https://druglandscape.com/ci/bcx4161. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab